Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222

Background: While there have been many studies characterizing the IgG and IgA responses to different SARS-CoV-2 proteins in individuals with natural infection, the induction of IgG and IgA to different viral proteins in vaccinees have not been extensively studied. Therefore, we sought to investigate the antibody responses to SARS-CoV-2 following natural infection and following a single dose of AZD2221, in Sri Lankan individuals. Methods: Using Luminex assays, we characterized the IgG and IgA responses in patients with varying severity of illness and following a single dose of the vaccine at 4 weeks and 12 weeks since onset of illness or following vaccination. Haemagglutination test (HAT) was used to assess the antibodies to the receptor binding domain of SARS-CoV-2 wild type (WT), B.1.1.7, B.1.351 and B.1.617.2 (VOCs) and surrogate neutralizing test to measure ACE2 receptor blocking antibodies. Results: Those with mild illness and in vaccinees, the IgG responses to S1, S2, RBD and N protein increased from 4 weeks to 12 weeks, while it remained unchanged in those with moderate/severe illness. Those who had a febrile illness in 2017 and 2018 (controls) also gave IgG and IgA high responses to the S2 subunit. In the vaccinees, the most significant rise was seen for the IgG antibodies to the S2 subunit (p<0.0001). Vaccinees had several fold lower IgA antibodies to all the SARS-CoV-2 proteins tested than those with mild and moderate/severe illness at 4 weeks and 12 weeks. At 12 weeks the HAT titres were significantly lower to the B.1.1.7 in vaccinees and significantly lower in those with mild illness, and in vaccinees to B.1.351 and for B.1.617.2. No such difference was seen in those with moderate/severe illness. Conclusions: Vaccinees had significantly less IgA to SARS-CoV-2, but comparable IgG responses to those with natural infection. However, following a single dose, vaccinees had reduced antibody levels to the variants of concern (VOC), which further declined with time, compared to natural infection.

[1]  L. Abu-Raddad,et al.  Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections , 2021, The New England journal of medicine.

[2]  P. Simmonds,et al.  Comparability of six different immunoassays measuring SARS‐CoV‐2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction , 2021, Transfusion.

[3]  G. Ogg,et al.  Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers , 2021, Nature Communications.

[4]  G. Ogg,et al.  Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARS‑CoV‑2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients , 2021, International Journal of Infectious Diseases.

[5]  R. Selvarangan,et al.  Cross-reactive antibody immunity against SARS-CoV-2 in children and adults , 2021, Cellular & Molecular Immunology.

[6]  Gareth Iacobucci Covid-19: Single vaccine dose is 33% effective against variant from India, data show , 2021, BMJ.

[7]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[8]  Scott L. Bain,et al.  COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study , 2021, The Lancet.

[9]  G. Ogg,et al.  Antibody and T-cell responses to a single dose of the AZD1222/Covishield vaccine in previously SARS-CoV-2 infected and naive health care workers in Sri Lanka , 2021, medRxiv.

[10]  A. Wisnewski,et al.  Human IgG and IgA responses to COVID-19 mRNA vaccines , 2021, medRxiv.

[11]  K. Mølbak,et al.  Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.

[12]  R. Rubin COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough. , 2021, JAMA.

[13]  N. G. Davies,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[14]  N. Jewell,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, medRxiv.

[15]  D. Stuart,et al.  Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera , 2021, Cell.

[16]  D. Lauffenburger,et al.  Humoral signatures of protective and pathological SARS-CoV-2 infection in children , 2021, Nature Medicine.

[17]  Nuno R. Faria,et al.  Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence , 2021, The Lancet.

[18]  J. Dubuisson,et al.  Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals , 2020, Frontiers in Microbiology.

[19]  P. Klenerman,et al.  A haemagglutination test for rapid detection of antibodies to SARS-CoV-2 , 2020, Nature Communications.

[20]  K. Järvinen,et al.  Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk , 2020, Journal of Perinatology.

[21]  Guozhong Zhang,et al.  Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19 , 2020, Signal Transduction and Targeted Therapy.

[22]  G. Ogg,et al.  SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness , 2020, Scientific Reports.

[23]  Francisco A. Chaves,et al.  S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit , 2020, mBio.

[24]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[25]  M. Roser,et al.  Coronavirus Pandemic (COVID-19) , 2020 .

[26]  Christopher Earl,et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans , 2020, Science.

[27]  H. Hakonarson,et al.  Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients , 2020, European Respiratory Journal.

[28]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.